Theraptosis

France Founded: 2001 • Age: 25 yrs
Develops innovative therapeutic molecules for oncology and neurodegenerative diseases.
Annual revenue $403,091 Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 8 Brand Intelligence

About Theraptosis

Theraptosis is a company based in France founded in 2001. It operates as a B2B. Theraptosis operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Denali Therapeutics, C4 Therapeutics and Erasca, among others.

  • Headquarter France
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Jurisdiction Bangalore North, Karnataka, India
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $403.09 K (USD)
    19.31
    as on Mar 31, 2022
  • Net Profit
    $26.11 K (USD)
    -14.87
    as on Mar 31, 2022
  • EBITDA
    $31.2 K (USD)
    28.43
    as on Mar 31, 2022
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Theraptosis

Premium access

Detailed funding history for Theraptosis

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Theraptosis

Investments
Premium access

Investment portfolio details for Theraptosis

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Theraptosis

Premium access

Detailed financials for Theraptosis

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Theraptosis Comparisons

Theraptosis Primary company
Description
Develops innovative therapeutic molecules for oncology and n...
Location
France
Founded Year
2001
Annual Revenue
$403.09 K (USD)
Net Profit
$26.11 K (USD)
EBITDA
$31.2 K (USD)
Employees
Not available
Premium access

Peer comparison for Theraptosis

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Theraptosis

Theraptosis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Denali Therapeutics, C4 Therapeutics and Erasca, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Therapies for neurodegenerative and immunology disorders are developed.
Locked Locked Locked
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
Locked Locked Locked
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
Locked Locked Locked
Small molecule therapeutics for cancer treatment are developed.
Locked Locked Locked
Cancer therapies are developed using selective pathway inhibitors.
Premium access

Detailed competitors of Theraptosis

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Theraptosis

Premium access

Complete news archive for Theraptosis

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Theraptosis

Theraptosis was founded in 2001.

Theraptosis is headquartered in France.

Annual revenue of Theraptosis is $403.09K as on Mar 31, 2022.

Theraptosis, established in 2001, excels in providing healthcare solutions, advancing biotech innovations, therapeutics, and oncology and neurodegenerative treatments. Develops innovative therapeutic molecules for oncology and neurodegenerative diseases. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.

Theraptosis's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available